Pterygium thickness did not meaningfully correlate with keratometry, astigmatism, irregularity indices, or most HOA metrics, suggesting depth contributes less to optical degradation than planar extent ...

An offline, point-of-care algorithm on a smartphone fundus camera generated disease-specific outputs without cloud connectivity, addressing a major deployment barrier in low-resource screening ...

To explore what the veligrotug approval means for patients and practice, Ophthalmology Times posed the same questions to several TED specialists, including the following: Raymond S. Douglas, MD, PhD, ...

4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...

Geographic atrophy can emerge during stable anti-VEGF regimens for bilateral wet AMD, requiring deliberate surveillance and patient counseling rather than “treat-and-forget” follow-up. Coordinating ...

Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...

In this podcast, experts Mary Qiu, MD; Paul Singh, MD; and Danica J. Marrelli, OD, FAAO; discuss interventional glaucoma. This more proactive management approach aims to minimize the challenges of ...

Peripheral retinal lesions occurred in 54.4% of highly myopic pediatric eyes, were bilateral in 64.2%, and increased in prevalence and multiplicity with age and more negative spherical equivalent.

How faricimab reshapes DME care: trial vs real-world durability, Ang2/VEGF clues, when to switch, and how AI-guided OCT may help. This episode, titled “Dosing Frequency Across Retinal Vascular ...

Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...